<i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

Abstract

PARP inhibition is a potential strategy for treating patients with gastric cancer with mutated BRCA2 or homologous repair deficiency, including patients with familial intestinal gastric cancer, for whom BRCA2 germline testing should be recommended.